Skip to main
PMN

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences Inc. has demonstrated a positive outlook, particularly with its Alzheimer’s candidate, PMN310, which has shown a favorable safety profile lacking amyloid-related imaging abnormalities (ARIA) in clinical trials, potentially positioning it as a safer alternative to other marketed anti-amyloid antibodies. The company has successfully advanced PMN310 to over 85% enrollment in its Phase Ib PRECISE-AD study, with upcoming 6-month data expected to be released in Q2 2026, further underpinning investor confidence. The Alzheimer’s market represents a substantial and rapidly expanding commercial opportunity, providing a compelling backdrop for ProMIS's growth prospects as it continues to innovate within the biotechnology realm.

Bears say

ProMIS Neurosciences Inc reported a net loss of $11.6 million for the third quarter of 2025, equating to a loss of $0.24 per share, indicating ongoing financial concerns that are characteristic of clinical-stage biotechnology firms. The company faces significant challenges including potential partnership risks, increased competition affecting market uptake, and the risk of dilution due to future financing needs before achieving cash flow positive status. Additionally, the lack of demonstrated efficacy and safety for its lead candidate, PMN310, amidst a competitive landscape poses substantial regulatory and commercial risks that contribute to the negative outlook for the company's stock.

PMN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 3 analysts, PMN has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.